Get the Stockscreener App
1.13
1.51%
-0.00
Hoth Therapeutics Inc stock is traded at $1.13, with a volume of 20,463.
It is down -1.51% in the last 24 hours and up +34.04% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
20,463
Relative Volume:
0.02
Market Cap:
$16.51M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.8561
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
-9.15%
1M Performance:
+34.04%
6M Performance:
+46.22%
1Y Performance:
+22.39%
1-Day Range:
$1.11
$1.135
1-Week Range:
$1.11
$1.3399
52-Week Range:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.13 | 16.51M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.24 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.20 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.75 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa
Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com
Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener
Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus
Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan
Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX
Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan
Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener
Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com
Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan
Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa
Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener
Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener
HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus
Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan
Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire
First-Ever Treatment for EGFR Cancer Therapy Skin Toxicities: Experts Review Game-Changing Clinical Data - Stock Titan
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by Wall Street Zen - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Shares Up 0.7% – What’s Next? - Defense World
Hoth Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Hoth Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HOTH THERAPEUTICS Earnings Results: $HOTH Reports Quarterly Earnings - Nasdaq
Hoth Therapeutics reports promising HT-KIT preclinical results By Investing.com - Investing.com Canada
Hoth Therapeutics, Inc. SEC 10-Q Report - TradingView
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers - PR Newswire
Hoth Therapeutics reports promising HT-KIT preclinical results - Investing.com Australia
Hoth Therapeutics (HOTH) Expected to Announce Earnings on Tuesday - Defense World
Geode Capital Management LLC Purchases 13,038 Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) - Defense World
Hoth Therapeutics confirms patent application fee payment By Investing.com - Investing.com Nigeria
Hoth Therapeutics confirms patent application fee payment - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models - Curetoday
Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT GeneExpands Global IP in Precision Oncology Platform - PR Newswire
Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus
Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - marketscreener.com
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):